New York, NY (PRWEB) August 28, 2012
A global leader in comprehensive, integrated medical and science information database platforms, Medmeme, LLC., released a syndicated TrendsmemeTM Report: Cardiology describing the comprehensive status of the hypertension indication, treatments, and drug market. An alarming potential impact of this indication is its connection with other serious diseases (diabetes, stroke, metabolic syndrome, and particularly the epidemic of obesity). Contribution to preventing a collision course of combined disease burden in the multiple disease areas could be an important opportunity for pharmaceutical firms in the overall cardiovascular treatment marketplace.
The U.S. Centers for Disease Control and Prevention (CDC) estimates that approximately 68 million people 18+ years old, over one-third of the U.S. population, has hypertension. It finds 48 million people with hypertension (70%) received drug treatment, yet only about half (46% or 31 million people of the total population with hypertension) has their blood pressure adequately controlled. And, because hypertension is a silent condition, many people remain undiagnosed—and therefore untreated. Recent annual U. S. health care costs related to hypertension are estimated to be approximately $47 billion.
The Medmeme report presents details of the overall cardiovascular marketplace describing how it will be saturated by year-end with inexpensive generic alternatives for nearly all key drug classes - including hypertension, congestive heart failure, and hyperlipidemia - and how leading hypertension companies have placed significant focus on extending the life cycles of their current drug franchises through line extensions in the form of double and triple combinations of well-established drugs. Fixed-dose therapies from distinct drug classes may be an improved way to meet the needs of various subpopulations of patients within this broad therapeutic category, and perhaps beyond.
There are also several new drugs with novel mechanisms in late-stage clinical trials for cardiovascular disease discussed in the report, including renin inhibitors for hypertension, CETP inhibitors for hyperlipidemia, and a variety of approaches for acute heart failure. For hypertension alone, the charts and graphs from the Medmeme database indicate that there has been a high level of activity in medical meeting presentations and medical journal articles published on new developments for the hypertension indication. For the most recent three years there were more than 6,600 meeting presentations and more than 2,600 articles focusing on hypertension.
The most active companies presenting hypertension information at meetings and in journals were: Abbott, AstraZeneca, Bristol-Myers Squibb, Pfizer, Merck, and Novartis. Other companies active in the therapeutic category discussed in the report are: Actelion, Boehringer Ingelheim, Cardiorentis, Cytokinetics/Amgen, Daiichi-Sankyo, Isis/Genzyme, Janssen Pharmaceuticals/Bayer, and Takeda. Other related topics of significance reported from the database were the considerations of genetics, lifestyle, quality of life, diabetes, elderly patients, and obesity, as they relate to cardiovascular disease.
The syndicated TrendsmemeTM Report: Cardiology can be purchased separately, or, along with other MedMeme reports in the new series, such as TrendsmemeTM Report: Metabolic Disease, at discounted pricing. To learn more, contact Medmeme, or see the website, http://www.medmeme.com/products/syndicated-reports/reports/trendsmeme-reports
Yan Barshay, Executive Vice President
Ray Wright, Vice President, Sales
+ 1 508-278-4595